Intravacc announces the publication of a GMP (Good Manufacturing Practices) process for a semi-synthetic Shigella glycoconjugate vaccine candidate developed at the Institut Pasteur (Paris).
Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, announced the publication of a GMP (Good Manufacturing Practices) manufacturing and formulation process for a monovalent semi-synthetic conjugate vaccine candidate against Shigella flexneri 2a (SF2a).
This candidate vaccine was developed at the Institut Pasteur (Paris, France) and the GMP process is described in the peer reviewed scientific journal ACS Central Science of the American Chemical Society, in a paper entitled The first-in-human synthetic glycan-based conjugate vaccine candidate against Shigella.
For more information, please visit
